Historical Valuation
Rani Therapeutics Holdings Inc (RANI) is now in the Fair zone, suggesting that its current forward PS ratio of 11.29 is considered Fairly compared with the five-year average of -5.46. The fair price of Rani Therapeutics Holdings Inc (RANI) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.38
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Rani Therapeutics Holdings Inc (RANI) has a current Price-to-Book (P/B) ratio of -8.30. Compared to its 3-year average P/B ratio of 7.30 , the current P/B ratio is approximately -213.65% higher. Relative to its 5-year average P/B ratio of 6.41, the current P/B ratio is about -229.40% higher. Rani Therapeutics Holdings Inc (RANI) has a Forward Free Cash Flow (FCF) yield of approximately -20.94%. Compared to its 3-year average FCF yield of -70.72%, the current FCF yield is approximately -70.39% lower. Relative to its 5-year average FCF yield of -51.88% , the current FCF yield is about -59.64% lower.
P/B
Median3y
7.30
Median5y
6.41
FCF Yield
Median3y
-70.72
Median5y
-51.88
Competitors Valuation Multiple
AI Analysis for RANI
The average P/S ratio for RANI competitors is 79.61, providing a benchmark for relative valuation. Rani Therapeutics Holdings Inc Corp (RANI.O) exhibits a P/S ratio of 11.29, which is -85.82% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RANI
1Y
3Y
5Y
Market capitalization of RANI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RANI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RANI currently overvalued or undervalued?
Rani Therapeutics Holdings Inc (RANI) is now in the Fair zone, suggesting that its current forward PS ratio of 11.29 is considered Fairly compared with the five-year average of -5.46. The fair price of Rani Therapeutics Holdings Inc (RANI) is between to according to relative valuation methord.
What is Rani Therapeutics Holdings Inc (RANI) fair value?
RANI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Rani Therapeutics Holdings Inc (RANI) is between to according to relative valuation methord.
How does RANI's valuation metrics compare to the industry average?
The average P/S ratio for RANI's competitors is 79.61, providing a benchmark for relative valuation. Rani Therapeutics Holdings Inc Corp (RANI) exhibits a P/S ratio of 11.29, which is -85.82% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Rani Therapeutics Holdings Inc (RANI) as of Jan 10 2026?
As of Jan 10 2026, Rani Therapeutics Holdings Inc (RANI) has a P/B ratio of -8.30. This indicates that the market values RANI at -8.30 times its book value.
What is the current FCF Yield for Rani Therapeutics Holdings Inc (RANI) as of Jan 10 2026?
As of Jan 10 2026, Rani Therapeutics Holdings Inc (RANI) has a FCF Yield of -20.94%. This means that for every dollar of Rani Therapeutics Holdings Inc’s market capitalization, the company generates -20.94 cents in free cash flow.
What is the current Forward P/E ratio for Rani Therapeutics Holdings Inc (RANI) as of Jan 10 2026?
As of Jan 10 2026, Rani Therapeutics Holdings Inc (RANI) has a Forward P/E ratio of -2.58. This means the market is willing to pay $-2.58 for every dollar of Rani Therapeutics Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Rani Therapeutics Holdings Inc (RANI) as of Jan 10 2026?
As of Jan 10 2026, Rani Therapeutics Holdings Inc (RANI) has a Forward P/S ratio of 11.29. This means the market is valuing RANI at $11.29 for every dollar of expected revenue over the next 12 months.